Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
Active, not recruiting · NCT03245021 · Registry updated 2024-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2024-07-30 | NCT03245021 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Dr. Eliza Hawkes | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Heidelberg | Australia | 70 |
| Ballarat Health | Ballarat | Australia | 1 |
| Eastern Health | Box Hill | Australia | 15 |
| Monash Health | Clayton | Australia | 2 |
| St Vincent's Hospital | Melbourne | Australia | 3 |